[1] Graham SV. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clin Sci, 2017; 131, 2201−21. doi:  10.1042/CS20160786
[2] Yang X, Cheng YX, Li CS. The role of TLRs in cervical cancer with HPV infection: a review. Signal Transduct Target Ther, 2017; 2, 17055. doi:  10.1038/sigtrans.2017.55
[3] Espinoza H, Ha KT, Pham TT, et al. Genetic predisposition to persistent human papillomavirus-infection and virus-induced cancers. Microorganisms, 2021; 9, 2092. doi:  10.3390/microorganisms9102092
[4] Torres-Poveda K, Bahena-Román M, Delgado-Romero K, et al. A prospective cohort study to evaluate immunosuppressive cytokines as predictors of viral persistence and progression to pre-malignant lesion in the cervix in women infected with HR-HPV: study protocol. BMC Infect Dis, 2018; 18, 582. doi:  10.1186/s12879-018-3490-1
[5] Long DL, Song HL, Qu PP. Cytokines profiles in cervical mucosa in patients with cervical high-risk human papillomavirus infection. J Infect Dev Ctries, 2021; 15, 719−25. doi:  10.3855/jidc.12147
[6] Ntuli L, Mtshali A, Mzobe G, et al. Role of immunity and vaginal microbiome in clearance and persistence of human papillomavirus infection. Front Cell Infect Microbiol, 2022; 12, 927131. doi:  10.3389/fcimb.2022.927131
[7] Torres-Poveda K, Burguete-García AI, Bahena-Román M, et al. Risk allelic load in Th2 and Th3 cytokines genes as biomarker of susceptibility to HPV-16 positive cervical cancer: a case control study. BMC Cancer, 2016; 16, 330. doi:  10.1186/s12885-016-2364-4
[8] Li BH, Zhang L, Zhao JG, et al. The value of cytokine levels in triage and risk prediction for women with persistent high-risk human papilloma virus infection of the cervix. Infect Agents Cancer, 2019; 14, 16. doi:  10.1186/s13027-019-0231-z
[9] Zheng JJ, Miao JR, Wu Q, et al. Correlation between HPV-negative cervical lesions and cervical microenvironment. Taiwan J Obstet Gynecol, 2020; 59, 855−61. doi:  10.1016/j.tjog.2020.08.002
[10] Peghini BC, Abdalla DR, Barcelos ACM, et al. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. Hum Immunol, 2012; 73, 920−6. doi:  10.1016/j.humimm.2012.06.003
[11] Scott ME, Shvetsov YB, Thompson PJ, et al. Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study. Int J Cancer, 2013; 133, 1187−96. doi:  10.1002/ijc.28119
[12] Lin W, Niu ZY, Zhang HL, et al. Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer. Int J Clin Exp Pathol, 2019; 12, 3604−12.
[13] Sasagawa T, Takagi H, Makinoda S. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother, 2012; 18, 807−15. doi:  10.1007/s10156-012-0485-5
[14] Daniilidis A, Koutsos J, Oikonomou Z, et al. Cytokines of cervical mucosa and human papilloma virus infection of the cervix: a descriptive study. Acta Cytol, 2016; 60, 58−64. doi:  10.1159/000445161
[15] Fernandes JV, de Medeiros Fernandes TAA, de Azevedo JCV, et al. Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncol Lett, 2015; 9, 1015−26. doi:  10.3892/ol.2015.2884
[16] Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and cox regression. Am J Epidemiol, 2007; 165, 710−8. doi:  10.1093/aje/kwk052